Glutamate receptor abnormalities in schizophrenia: implications for innovative treatments.
about
In Sickness and in Health: Perineuronal Nets and Synaptic Plasticity in Psychiatric DisordersAutoantibodies to central nervous system neuronal surface antigens: psychiatric symptoms and psychopharmacological implicationsThe ameliorating effects of 5,7-dihydroxy-6-methoxy-2(4-phenoxyphenyl)-4H-chromene-4-one, an oroxylin A derivative, against memory impairment and sensorimotor gating deficit in miceDendropanax morbifera Léveille extract ameliorates cadmium-induced impairment in memory and hippocampal neurogenesis in ratsThe role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue.The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies.Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia.What causes aberrant salience in schizophrenia? A role for impaired short-term habituation and the GRIA1 (GluA1) AMPA receptor subunit.Effects of Immune Activation during Early or Late Gestation on N-Methyl-d-Aspartate Receptor Measures in Adult Rat Offspring.Characterization of a Novel Mutation in SLC1A1 Associated with Schizophrenia.Altered Glutamate and Regional Cerebral Blood Flow Levels in Schizophrenia: A 1H-MRS and pCASL study.Safety, Tolerability and Pharmacokinetics of Oral BI 425809, a Glycine Transporter 1 Inhibitor, in Healthy Male Volunteers: A Partially Randomised, Single-Blind, Placebo-Controlled, First-in-Human Study.Standardized Prunella vulgaris var. lilacina Extract Enhances Cognitive Performance in Normal Naive Mice.Neurotoxic Agent-Induced Injury in Neurodegenerative Disease Model: Focus on Involvement of Glutamate Receptors
P2860
Q26769948-B59F6401-FAD6-4C77-B47A-536BB9D846D9Q26775915-AEE30F62-F314-4C13-A8CE-BB419FB1F867Q28288084-E93AF661-CA18-4032-9BD6-C615422D30DBQ28393790-FEE3BDEA-783A-47C7-B1EB-FE60D396C6BBQ30437188-864C51E3-656D-4042-B97E-E43A0F135C77Q35186635-E0CCE733-D2EC-425E-9AC8-831F6E8D35B6Q38094683-EA7C5002-F9E1-43F4-B900-423901F30240Q38249908-88FCE53E-072C-4F4D-9836-D9E1C177241BQ41471608-3F27978B-D5A0-43EA-A934-E66AFD463A21Q42154902-CB517493-5BAB-4578-AF0D-275AFF113C07Q43538712-B9487CB1-6A31-4826-82A4-050935008CB6Q48117897-12D471EE-6253-4A24-B5DA-76237437307EQ50561053-269FA2D5-2DCB-4C0D-9686-1A4DC41D5287Q58694067-E9CB281C-079F-4E45-835B-144747CE7FD4
P2860
Glutamate receptor abnormalities in schizophrenia: implications for innovative treatments.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Glutamate receptor abnormaliti ...... ons for innovative treatments.
@en
type
label
Glutamate receptor abnormaliti ...... ons for innovative treatments.
@en
prefLabel
Glutamate receptor abnormaliti ...... ons for innovative treatments.
@en
P2093
P2860
P1476
Glutamate receptor abnormaliti ...... ons for innovative treatments.
@en
P2093
James H Meador-Woodruff
Jana B Drummond
Maria D Rubio
P2860
P356
10.4062/BIOMOLTHER.2012.20.1.001
P577
2012-01-01T00:00:00Z